Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status:
Terminated

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.

Phase 2

Novartis Pharmaceuticals